ECOD
F-group (family)

284.1.1.1 FKBP_C

Open in classification tree →Pfam PF00254 →

Ligands and drugs

2,521
Member domains
457
with ligand contacts (≤ 4 Å)
18.1% of members
329
with DrugDomain annotations
13.1% of members
188
with a DrugBank compound
7.5% of members

Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.

Chemical profile

Chemical profiles are computed for X-groups. 284.1.1.1 belongs to X-group 284 FKBP-like, which binds 9.3 ligand superclasses per 20 proteins, broader than 84% of the 256 X-groups with enough proteins to compare. View its chemical profile →

DrugBank compounds

DrugBankPDB ligandNameDomains
DB00864FK5Tacrolimus56
DB00877RAPSirolimus26
DB02888001FKB-0013
DB01723AP1{3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid2
DB02311DSSMethyl Methylsulfinylmethyl Sulfide2
DB03621587L-709,5872
DB04094BUQ4-hydroxybutan-2-one2
DB04349PGO(S)-propane-1,2-diol2
DB08520SB1(21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE2
DB00337——1
DB01712SUB(3R)-4-(p-toluenesulfonyl)-1,4-thiazane-3-carboxylicacid-L-phenylalanine ethyl ester1
DB01951GPIGpi-10461
DB02175MLAMalonic acid1
DB02184DTVD-1,4-dithiothreitol1
DB02701NCANicotinamide1
DB03338B7GHeptyl glucoside1
DB033854MZ4-Methylimidazole1
DB03434MPO3-(N-morpholino)propanesulfonic acid1
DB04012TST(3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine1
DB04417NPOP-Nitrophenol1

Most frequently bound compounds

PDB ligandNameDomains in contact
FK58-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN59
CLCHLORIDE ION33
RAPRAPAMYCIN IMMUNOSUPPRESSANT DRUG27
CAmetalCALCIUM ION15
NAmetalSODIUM ION12
ZNmetalZINC ION9
MGmetalMAGNESIUM ION7
R27N'-[(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-1,20,21-trioxo-8-(prop-2-en-1-yl)-1,3,4,5,6,8,11,12,13,14,15,16,17,18,19,20,21,23,24,25,26,26a-docosahydro-7H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosin-7-ylidene]acetohydrazide7
8613-(3,4,5-trimethoxyphenyl)propyl (2S)-1-(benzylsulfonyl)piperidine-2-carboxylate6
CDmetalCADMIUM ION5
UUI(1S,5S,6R)-10-[[3,5-bis(chloranyl)phenyl]sulfonimidoyl]-5-ethenyl-3-(pyridin-2-ylmethyl)-3,10-diazabicyclo[4.3.1]decan-2-one5
60Z(3R,4E,7E,10R,11S,12R,13S,16R,17R,24aS)-11,17-dihydroxy-10,12,16-trimethyl-3-[(2R)-1-phenylbutan-2-yl]-6,9,10,11,12,13,14,15,16,17,22,23,24,24a-tetradecahydro-3H-13,17-epoxypyrido[2,1-c][1,4]oxazacyclohenicosine-1,18,19(21H)-trione4
6UO2-[(2~{S})-1-(phenylmethyl)sulfonylpiperidin-2-yl]carbonyloxyethyl pyridine-3-carboxylate4
A1IN3(2~{S},9~{S},14~{E})-2-cyclohexyl-20,23-dimethoxy-11,18-dioxa-4-azatricyclo[17.2.2.0^{4,9}]tricosa-1(22),14,19(23),20-tetraene-3,10-dione4
D44N-(2-ethylphenyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylsulfanyl)acetamide4
GY12-[3-[(1~{R})-1-[(2~{S})-1-[(2~{S})-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)ethanoyl]piperidin-2-yl]carbonyloxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]ethanoic acid4
LLD2-(pyridin-3-ylcarbonylamino)ethyl (2~{S})-1-(phenylmethyl)sulfonylpiperidine-2-carboxylate4
UQI(1S,5S,6R)-10-[[3,5-bis(chloranyl)phenyl]sulfonimidoyl]-5-ethenyl-3-(pyridin-2-ylmethyl)-3,10-diazabicyclo[4.3.1]decan-2-one4
XYU(3S,5R,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,30R,34aS)-5,9,27-trihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-5,6,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-octadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,11,28,29(4H,31H)-tetrone4
0011-[2,2-DIFLUORO-2-(3,4,5-TRIMETHOXY-PHENYL)-ACETYL]-PIPERIDINE-2-CARBOXYLIC ACID4-PHENYL-1-(3-PYRIDIN-3-YL-PROPYL)-BUTYL ESTER3